메뉴 건너뛰기




Volumn 7, Issue 1, 2014, Pages 241-249

Simeprevir for the treatment of hepatitis C virus infection

Author keywords

Direct acting antiviral agent; Hepatitis C virus; Protease inhibitor; Simeprevir

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; PLACEBO; PROTEINASE; RIBAVIRIN; RIFAMPICIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

EID: 84921409702     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S52715     Document Type: Review
Times cited : (51)

References (42)
  • 1
    • 59149085501 scopus 로고    scopus 로고
    • The global burden of hepatitis C
    • Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74-81.
    • (2009) Liver Int , vol.29 , Issue.1 , pp. 74-81
    • Lavanchy, D.1
  • 2
    • 79959438789 scopus 로고    scopus 로고
    • ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.
    • (2011) N Engl J Med , vol.364 , Issue.25 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3
  • 3
    • 79959381354 scopus 로고    scopus 로고
    • REALIZE Study Team. Telaprevir for retreatment of HCV infection
    • Zeuzem S, Andreone P, Pol S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25): 2417-2428.
    • (2011) N Engl J Med , vol.364 , Issue.25 , pp. 2417-2428
    • Zeuzem, S.1    Andreone, P.2    Pol, S.3
  • 4
    • 79953176289 scopus 로고    scopus 로고
    • HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection
    • Bacon BR, Gordon SC, Lawitz E, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-1217.
    • (2011) N Engl J Med , vol.364 , Issue.13 , pp. 1207-1217
    • Bacon, B.R.1    Gordon, S.C.2    Lawitz, E.3
  • 5
    • 79953173221 scopus 로고    scopus 로고
    • SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection
    • Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.
    • (2011) N Engl J Med , vol.364 , Issue.13 , pp. 1195-1206
    • Poordad, F.1    McCone Jr., J.2    Bacon, B.R.3
  • 6
    • 84895074600 scopus 로고    scopus 로고
    • Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: The DRAGON study
    • Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49(1):138-147.
    • (2014) J Gastroenterol , vol.49 , Issue.1 , pp. 138-147
    • Hayashi, N.1    Seto, C.2    Kato, M.3    Komada, Y.4    Goto, S.5
  • 7
    • 84885815731 scopus 로고    scopus 로고
    • Hepatitis C genotype 6: A concise review and response-guided therapy proposal
    • Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: a concise review and response-guided therapy proposal. World J Hepatol. 2013;5(9):496-504.
    • (2013) World J Hepatol , vol.5 , Issue.9 , pp. 496-504
    • Bunchorntavakul, C.1    Chavalitdhamrong, D.2    Tanwandee, T.3
  • 8
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.
    • (2002) N Engl J Med , vol.347 , Issue.13 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 9
    • 68249154875 scopus 로고    scopus 로고
    • IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    • McHutchison JG, Lawitz EJ, Shiffman ML, et al; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-593.
    • (2009) N Engl J Med , vol.361 , Issue.6 , pp. 580-593
    • McHutchison, J.G.1    Lawitz, E.J.2    Shiffman, M.L.3
  • 10
    • 84855209804 scopus 로고    scopus 로고
    • Direct acting antivirals for the treatment of chronic hepatitis C: One pill a day for tomorrow
    • Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 2012; 32(Suppl 1):88-102.
    • (2012) Liver Int , vol.32 , Issue.1 , pp. 88-102
    • Asselah, T.1    Marcellin, P.2
  • 11
    • 84856410313 scopus 로고    scopus 로고
    • Antiviral strategies in hepatitis C virus infection
    • Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56(Suppl 1):S88-S100.
    • (2012) J Hepatol , vol.56 , Issue.1
    • Sarrazin, C.1    Hézode, C.2    Zeuzem, S.3    Pawlotsky, J.M.4
  • 12
    • 84886914803 scopus 로고    scopus 로고
    • Hepatitis C virus: Virology and life cycle
    • Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013;19(1):17-25.
    • (2013) Clin Mol Hepatol , vol.19 , Issue.1 , pp. 17-25
    • Kim, C.W.1    Chang, K.M.2
  • 13
    • 84879420038 scopus 로고    scopus 로고
    • The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
    • Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11(7):482-496.
    • (2013) Nat Rev Microbiol , vol.11 , Issue.7 , pp. 482-496
    • Bartenschlager, R.1    Lohmann, V.2    Penin, F.3
  • 14
    • 55249124522 scopus 로고    scopus 로고
    • Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors
    • Liang Y, Ishida H, Lenz O, et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology. 2008;135(5):1710-1718. e2.
    • (2008) Gastroenterology , vol.135 , Issue.5 , pp. 1710-1718
    • Liang, Y.1    Ishida, H.2    Lenz, O.3
  • 15
    • 75149151884 scopus 로고    scopus 로고
    • Resistance to direct antiviral agents in patients with hepatitis C virus infection
    • Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138(2): 447-462.
    • (2010) Gastroenterology , vol.138 , Issue.2 , pp. 447-462
    • Sarrazin, C.1    Zeuzem, S.2
  • 16
    • 65749112245 scopus 로고    scopus 로고
    • In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor
    • Lin TI, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother. 2009;53(4):1377-1385.
    • (2009) Antimicrob Agents Chemother , vol.53 , Issue.4 , pp. 1377-1385
    • Lin, T.I.1    Lenz, O.2    Fanning, G.3
  • 20
    • 77449158033 scopus 로고    scopus 로고
    • Rapid HCV-RNA decline with once daily TMC435: A phase I study in healthy volunteers and hepatitis C patients
    • Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138(3):913-921.
    • (2010) Gastroenterology , vol.138 , Issue.3 , pp. 913-921
    • Reesink, H.W.1    Fanning, G.C.2    Farha, K.A.3
  • 21
    • 84901434287 scopus 로고    scopus 로고
    • simeprevir, prescribing information, Stockholm: Medivir AB, Available from, Accessed December 1, 2013
    • Medivir AB. Olysio (simeprevir) capsule. Highlights of Prescribing Information [prescribing information]. Stockholm: Medivir AB: 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf. Accessed December 1, 2013.
    • (2013) Capsule. Highlights of Prescribing Information
    • Olysio, M.A.B.1
  • 22
    • 84887865879 scopus 로고    scopus 로고
    • Simeprevir for the treatment of chronic hepatitis C
    • You DM, Pockros PJ. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2013;14(18):2581-2589.
    • (2013) Expert Opin Pharmacother , vol.14 , Issue.18 , pp. 2581-2589
    • You, D.M.1    Pockros, P.J.2
  • 23
    • 84940251854 scopus 로고    scopus 로고
    • Phase I safety and PK of TMC435 in healthy volunteers and safety, PK and short-term efficacy in chronic hepatitis C infected individuals
    • Kobe, Japan, Abstract O-32
    • Verloes R, Shishido A. Phase I safety and PK of TMC435 in healthy volunteers and safety, PK and short-term efficacy in chronic hepatitis C infected individuals. Paper presented at: Japanese Hepatology Congress; June 4-5, 2009; Kobe, Japan. Abstract O-32 4-5.
    • (2009) Paper Presented At: Japanese Hepatology Congress , pp. 4-5
    • Verloes, R.1    Shishido, A.2
  • 26
    • 77951210464 scopus 로고    scopus 로고
    • In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435
    • Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010;54(5):1878-1887.
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.5 , pp. 1878-1887
    • Lenz, O.1    Verbinnen, T.2    Lin, T.I.3
  • 27
    • 78649644443 scopus 로고    scopus 로고
    • Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors
    • Bae A, Sun SC, Qi X, et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother. 2010;54(12):5288-5297.
    • (2010) Antimicrob Agents Chemother , vol.54 , Issue.12 , pp. 5288-5297
    • Bae, A.1    Sun, S.C.2    Qi, X.3
  • 28
    • 84888295678 scopus 로고    scopus 로고
    • Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study
    • Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918-1929.
    • (2013) Hepatology , vol.58 , Issue.6 , pp. 1918-1929
    • Fried, M.W.1    Buti, M.2    Dore, G.J.3
  • 29
    • 84892806505 scopus 로고    scopus 로고
    • Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
    • Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146(2):430-441. e6.
    • (2014) Gastroenterology , vol.146 , Issue.2 , pp. 430-441
    • Zeuzem, S.1    Berg, T.2    Gane, E.3
  • 30
    • 84901217985 scopus 로고    scopus 로고
    • Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A Phase 3 trial
    • Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a Phase 3 trial. Gastroenterology. 2014;146(7):1669-1679. e3.
    • (2014) Gastroenterology , vol.146 , Issue.7 , pp. 1669-1679
    • Forns, X.1    Lawitz, E.2    Zeuzem, S.3
  • 31
    • 84906053496 scopus 로고    scopus 로고
    • Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial
    • Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. Epub June 3 2014.
    • (2014) Lancet. Epub June , pp. 3
    • Jacobson, I.M.1    Dore, G.J.2    Foster, G.R.3
  • 32
    • 84906059095 scopus 로고    scopus 로고
    • Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial
    • Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. Epub June 3 2014.
    • (2014) Lancet. Epub June , pp. 3
    • Manns, M.1    Marcellin, P.2    Poordad, F.3
  • 33
    • 84868028511 scopus 로고    scopus 로고
    • Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy
    • Lenz O, de Bruijne J, Vijgen L, et al. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology. 2012;143(5):1176-1178. e1.
    • (2012) Gastroenterology , vol.143 , Issue.5 , pp. 1176-1178
    • Lenz, O.1    de Bruijne, J.2    Vijgen, L.3
  • 34
    • 80055076797 scopus 로고    scopus 로고
    • Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: A randomized trial
    • Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther. 2011;16(7):1021-1033.
    • (2011) Antivir Ther , vol.16 , Issue.7 , pp. 1021-1033
    • Manns, M.1    Reesink, H.2    Berg, T.3
  • 35
    • 84904723744 scopus 로고    scopus 로고
    • Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial
    • Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. Epub April 12, 2014.
    • (2014) J Hepatol. Epub April , pp. 12
    • Hayashi, N.1    Izumi, N.2    Kumada, H.3
  • 36
    • 84901451695 scopus 로고    scopus 로고
    • Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: The CONCERTO-2 and CONCERTO-3 studies
    • Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49(5):941-953.
    • (2014) J Gastroenterol , vol.49 , Issue.5 , pp. 941-953
    • Izumi, N.1    Hayashi, N.2    Kumada, H.3
  • 38
    • 84895074148 scopus 로고    scopus 로고
    • Once-daily simeprevir in combination with pegylated-interferon and ribavirin: A new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C
    • Maekawa S, Enomoto N. Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C. J Gastroenterol. 2014;49(1):163-164.
    • (2014) J Gastroenterol , vol.49 , Issue.1 , pp. 163-164
    • Maekawa, S.1    Enomoto, N.2
  • 39
    • 84902953427 scopus 로고    scopus 로고
    • CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis
    • Hezode C, Fontaine H, Dorival C, et al; CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. Epub April 3, 2014.
    • (2014) Gastroenterology. Epub April , pp. 3
    • Hezode, C.1    Fontaine, H.2    Dorival, C.3
  • 40
    • 84907447002 scopus 로고    scopus 로고
    • Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 Prior null responders with metavir f0-2: COSMOS study subgroup analysis
    • Sulkowski M, Jacobson IM, Ghalib R, et al. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 Prior null responders with metavir f0-2: COSMOS study subgroup analysis. J Hepatol. 2014;60(Suppl 1):S4.
    • (2014) J Hepatol , vol.60 , Issue.1
    • Sulkowski, M.1    Jacobson, I.M.2    Ghalib, R.3
  • 41
    • 84913532269 scopus 로고    scopus 로고
    • Daclatasvir in combination with simeprevir ± ribavirin for hepatitis C virus genotype 1 infection. Abstract presented at: 21st Conference on Retroviruses and Opportunistic Infections
    • Zeuzem S, Hezode C, Bronowicki J-PP, et al. Daclatasvir in combination with simeprevir ± ribavirin for hepatitis C virus genotype 1 infection. Abstract presented at: 21st Conference on Retroviruses and Opportunistic Infections. Topics Antiviral Med. 2014;22(Issue e-1):15.
    • (2014) Topics Antiviral Med , vol.22 , Issue.1 , pp. 15
    • Zeuzem, S.1    Hezode, C.2    Bronowicki, J.-P.P.3
  • 42
    • 84908096221 scopus 로고    scopus 로고
    • Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: Final results of a phase III trial. Poster presented at: 49th Annual meeting of the European Association for the Study of the Liver
    • Moreno C, Hezode C, Marcellin P, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial. Poster presented at: 49th Annual meeting of the European Association for the Study of the Liver. J Hepatology. 2014;60(Suppl 1):S535.
    • (2014) J Hepatology , vol.60 , Issue.1
    • Moreno, C.1    Hezode, C.2    Marcellin, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.